Somatostatin receptors (SS-Rs) are expressed in neuroendocrine tumour tissues where they can be targetted for diagnosis and therapy. This study investigated the presence of SS-Rs in nasopharyngeal carcinoma (NPC), a common cancer in South-East Asia. Nasopharynx biopsy specimens were obtained from 12 NPC patients and 5 patients without tumours. Somatostatin receptor autoradiography was performed using 125I-labelled [Tyr3]-octreotide and 125I-labelled [Leu8, DTrp22, Tyr25]-somatostatin-28 as radioligands. Of the 12 NPC samples 9 showed moderate to high expression of SS-Rs. These were of the sst2 type, based on the rank order of potency of subtype-selective analogues. The 5 non-neoplastic samples, consisting primarily of granulomatous tissue, did not express measurable amounts of SS-Rs. This study demonstrates for the first time the presence of type 2 SS-R in NPC. These receptors may play a role in the management of NPC, as is the case for other somatostatin-expressing tumours.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
About this article
Cite this article
Loh, K., Waser, B., Tan, .L. et al. Somatostatin receptors in nasopharyngeal carcinoma. Virchows Arch 441, 444–448 (2002). https://doi.org/10.1007/s00428-002-0693-y
- Diagnosis Scintigraphy Somatostatin receptors Treatment Nasopharyngeal carcinoma Peptides